AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) has been assigned an average rating of “Buy” from the nine analysts that are currently covering the stock. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $9.33.

A number of equities research analysts have commented on ACRX shares. Roth Capital upped their price target on AcelRx Pharmaceuticals from $11.25 to $15.00 and gave the company a “buy” rating in a research report on Thursday, September 15th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of AcelRx Pharmaceuticals in a research report on Thursday, September 8th. Jefferies Group reiterated a “buy” rating and issued a $7.00 price target on shares of AcelRx Pharmaceuticals in a research report on Tuesday, October 4th. Stifel Nicolaus lowered AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Finally, Cowen and Company restated a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, July 29th.

COPYRIGHT VIOLATION NOTICE: “AcelRx Pharmaceuticals Inc. (ACRX) Given Consensus Recommendation of “Buy” by Analysts” was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2016/11/26/acelrx-pharmaceuticals-inc-acrx-given-consensus-recommendation-of-buy-by-analysts.html.

In related news, major shareholder Perceptive Advisors Llc sold 392,850 shares of the company’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $3.70, for a total transaction of $1,453,545.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 27.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. purchased a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at about $155,000. California State Teachers Retirement System purchased a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at about $200,000. Bank of New York Mellon Corp raised its position in shares of AcelRx Pharmaceuticals by 142.4% in the second quarter. Bank of New York Mellon Corp now owns 145,477 shares of the specialty pharmaceutical company’s stock valued at $391,000 after buying an additional 85,459 shares during the last quarter. Nippon Life Insurance Co. purchased a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at about $2,247,000. Finally, WealthTrust Axiom LLC raised its position in shares of AcelRx Pharmaceuticals by 738.7% in the second quarter. WealthTrust Axiom LLC now owns 130,000 shares of the specialty pharmaceutical company’s stock valued at $349,000 after buying an additional 114,500 shares during the last quarter. Institutional investors and hedge funds own 36.15% of the company’s stock.

AcelRx Pharmaceuticals (NASDAQ:ACRX) opened at 3.05 on Monday. The firm’s 50 day moving average price is $3.12 and its 200 day moving average price is $3.23. AcelRx Pharmaceuticals has a 52-week low of $2.40 and a 52-week high of $5.85. The firm’s market cap is $138.27 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings results on Tuesday, November 1st. The specialty pharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.02. AcelRx Pharmaceuticals had a negative net margin of 347.94% and a negative return on equity of 232.39%. The company earned $1.60 million during the quarter, compared to the consensus estimate of $2.89 million. Equities research analysts anticipate that AcelRx Pharmaceuticals will post ($0.98) EPS for the current fiscal year.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

5 Day Chart for NASDAQ:ACRX

Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.